Wanlian Securities gives Maru Biotech an "Overweight" rating, with rapid revenue growth and expectations for future profit improvement.

NightAirdropper · 2026-04-07T01:57:59+00:00

Wanlian Securities maintains an "Overweight" rating for Marubi Biotech, citing reasons such as rapid revenue growth, product iteration, and improved gross profit margin. However, it faces risks from macroeconomic conditions and market competition. Meanwhile, major US economic data reduce the likelihood of a Federal Reserve rate cut, and Goldman Sachs indicates a low probability of rate hikes.

NightAirdropper

2026-04-07 01:57:59

Abstract generation in progress

Per the Every Daily AI Express, Wanlian Securities published a research report on April 6 stating that it gives Marubi Bio (603983.SH, latest price: 24.36 yuan) a “Buy” rating.

The main reasons for the rating include: 1) revenue grows relatively quickly, while profit faces short-term pressure; 2) products continue to iterate and introduce new offerings, with revenue from eye-area and skincare businesses growing rapidly; 3) the gross margin year over year improves, while the selling and administrative expense ratios increase by a larger amount.

Risk warning: macroeconomic recovery falls short of expectations; channel expansion does not meet expectations; brand building does not meet expectations; intensifying market competition.

Every Daily Headlines (nbdtoutiao) — Major U.S. data is released; this makes this year’s rate cuts by the Federal Reserve uncertain! Will it pivot to rate hikes? Goldman Sachs provides four reasons: “The possibility is very small.”

(Reporter: Zeng Jianhui)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using. Operating on this basis is at your own risk.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.